Full-Time

Neural Nexus AI Data Enablement

Director, Data & AI Enablement

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Engineering Management (1)
Required Skills
Data Engineering
Data Governance
Data Analysis
Requirements
  • Bachelor's degree or Master's degree with 18+ years of Industrial experience
  • 4 years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs or directing the allocation of resources
Responsibilities
  • Define and own the strategic roadmap for AuRA data enablement, aligned to Neural Nexus and enterprise data strategy
  • Translate business priorities into scalable platform capabilities and multi-year execution plans
  • Drive prioritization across initiatives, balancing speed, governance, scalability, and business impact
  • Own delivery of multiple, complex AuRA programs and workstreams, ensuring execution across design, build, deployment, and adoption
  • Establish strong execution discipline with clear ownership of scope, timelines, risks, and dependencies
  • Drive operational rigor through standardized delivery frameworks, metrics, and governance models
  • Lead the evolution of AuRA into a scalable, enterprise-grade AI-ready data platform
  • Define standards for data integration, modeling, metadata, and reusable data products
  • Ensure platform reliability, scalability, and performance across enterprise use cases
  • Establish and embed data governance and stewardship practices across AuRA initiatives
  • Ensure adherence to FAIR principles and Clean Core strategy while maintaining delivery velocity
  • Drive accountability for data ownership, lineage, quality, and lifecycle management
  • Build and lead a high-performing, cross-functional team across data engineering, analytics, and program management
  • Define clear roles, responsibilities, and performance expectations aligned to business outcomes
  • Foster a culture of ownership, accountability, and execution excellence
  • Coach and mentor leaders and team members, supporting career growth and capability development
  • Drive performance management, including goal setting, feedback, and recognition
  • Establish scalable team structures and operating models to support growing demand and complexity
  • Partner with Commercial, CD&A, Analytics, Technology, AI&D, and Engineering teams to align on priorities and execution
  • Influence senior stakeholders to drive alignment on data strategy, investments, and delivery outcomes
  • Enable effective collaboration across global, matrixed teams
  • Define and track KPIs for platform adoption, data usage, and business impact
  • Ensure data products are discoverable, trusted, and reusable
  • Drive measurable improvements in efficiency, insight generation, and decision-making
  • Lead change management efforts to support adoption of new data platforms, processes, and operating models
  • Continuously improve delivery processes, team effectiveness, and platform capabilities
  • Establish feedback loops for continuous improvement and sustained performance
Desired Qualifications
  • Proven experience building and scaling high-performing data and analytics teams
  • Strong experience in enterprise data platform implementation and data enablement at scale
  • Deep understanding of: Data architecture, pipelines, and platform design
  • Data governance, MDM, and data quality frameworks
  • AI/ML data readiness and enablement
  • Experience working with commercial pharma datasets (CRM, claims, HCP/HCO, patient data)
  • Strong executive presence with ability to influence senior stakeholders and drive alignment
  • Demonstrated success delivering large-scale, cross-functional programs with measurable impact

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.